Post Profile

Summit and Sarepta to collaborate on muscular dystrophy drug

(Reuters) - Drugmaker Sarepta Therapeutics Inc has entered into an exclusive license agreement with Britain's Summit Therapeutics Plc to develop drugs to treat Duchenne muscular dystrophy (DMD), the companies said on Tuesday.
read more

See more about: Sarepta Therapeutics

Related Posts

Sarepta's keenly watched muscle dystrophy drug wins FDA approval

Health : Reuters: Health

(Reuters) - Sarepta Therapeutics Inc's Duchenne muscular dystrophy drug won approval from the U.S. Food and Drug Administration on Monday, capping months of regulatory uncertainty and pressure from parents and patient advocates to e...

GlaxoSmithKline plc (ADR) (GSK), Sarepta Therapeutics Inc (SRPT): Could This DMD Treatment Become a Blockbuster Drug?

Business & Finance / Investing : Insider Monkey

Duchenne muscular dystrophy, or DMD, is a muscle-wasting disease caused by a genetic mutation in the dystrophin gene — the largest gene on the X chromosome — which affects one in every 2,400 male births. Muscle weakness in DMD patie...

Sarepta Wins FDA Nod For Embattled DMD Drug -- But With A Catch

Business & Finance : Forbes: Business

Just five days after its main nemesis at the FDA departed the agency, Sarepta Therapeutics has won a long-sought-after approval for eteplirsen, its drug to treat Duchenne muscular dystrophy (DMD). But the company's battle isn't over...

Anthem says will not cover Sarepta's approved Duchenne drug

Health : Reuters: Health

(Reuters) - Health insurer Anthem Inc said it will not cover Sarepta Therapeutics Inc's drug to treat the rare condition of Duchenne muscular dystrophy (DMD), calling it "investigational and not medically necessary."

Sarepta Therapeutics Inc (SRPT), GlaxoSmithKline plc (ADR) (GSK): An Edge Emerges in the Race to Treat Muscular Dystrophy

Business & Finance / Investing : Insider Monkey

In a previous article, I speculated on the race to develop a Duchenne muscular dystrophy, or DMD, drug and who might win it. It seems now that Sarepta Therapeutics Inc (NASDAQ:SRPT) has moved a step ahead after disappointing mid-sta...


Copyright © 2016 Regator, LLC